A Phase 2 interventional study of Luvadaxistat and Matching Placebo in Schizophrenia, sponsored by Neurocrine Biosciences. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.
Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 14th largest by enrollment, is one of 2 that started in 2018, is one of 6 in phase 2, and was the 4th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in Bulgaria, Romania, United Kingdom
Ages 18–55
Neurocrine Biosciences · Sites in United States, Puerto Rico, Serbia
Ages 18–65
Neurocrine Biosciences · Sites in United States
Ages 18+
Neurocrine Biosciences · Sites in United States, Bulgaria, Hungary and 2 more countries
Ages 18–65
Neurocrine Biosciences · Sites in United States, Bulgaria, Puerto Rico and 2 more countries
Ages 18–65
By country, each count listing its studies:
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2018.
This study's enrollment of 31 is below the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 165 across the 16 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Neurocrine Biosciences is the lead sponsor of 88 studies on the registry; 18 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
3 of the studies in Schizophrenia by Neurocrine Biosciences that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06963034Phase 3Neurocrine BiosciencesNBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | 2027-10 |
| NCT07105098Phase 3Neurocrine BiosciencesNBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | 2027-11 |
| NCT07288333Neurocrine BiosciencesEvaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Schizophrenia by Neurocrine Biosciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether luvadaxistat is superior to placebo in improving cerebellar function as measured with the average percentage of conditioned responses during the eyeblink conditioning (EBC) test.
The drug being tested in this study is called luvadaxistat. Luvadaxistat is being tested to treat people with schizophrenia.
Participants will be randomly assigned to one of the two treatment sequences which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
Participants will receive luvadaxistat 500 mg during the treatment period in which they are assigned to luvadaxistat. Following an interim analysis, there will be a study-wide decision about whether to treat the additional participants with luvadaxistat 500 mg during the active treatment period to or treat them with luvadaxistat 50 mg during this period. After the interim analysis, the participant and study doctor will not be aware of which luvadaxistat dose is being used.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants first received luvadaxistat 500 mg orally once daily (QD) for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received matching placebo orally QD for 8 days during treatment period 2.
Drug: Luvadaxistat · Drug: Matching Placebo
Participants first received matching placebo orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received luvadaxistat 500 mg orally QD for 8 days during treatment period 2.
Drug: Luvadaxistat · Drug: Matching Placebo
Participants first received luvadaxistat 50 mg orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received matching placebo orally QD for 8 days during treatment period 2.
Drug: Luvadaxistat · Drug: Matching Placebo
Participants first received matching placebo orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received luvadaxistat 50 mg orally QD for 8 days during treatment period 2.
Drug: Luvadaxistat · Drug: Matching Placebo
TAK-831 Tablets.
Also known as: TAK-831, NBI-1065844
Matching Placebo Tablets.
Change From Baseline in Average Percent of Conditioned Responses During the Eye Blink Conditioning (EBC) Test at Day 8
EBC is a method used to investigate cerebellar-dependent learning. In EBC, a conditioned stimulus, a tone precedes but co-terminates with an unconditioned stimulus, an airpuff to the eyelid. Learning is demonstrated when an eyeblink (the conditioned response) occurs prior to the onset of the unconditioned stimulus. The percentage can range from 0% (no conditioned learning has occurred) to 100% (all responses are conditioned). Results are reported as least squares (LS) means at Day 8, determined using an analysis of variance (ANOVA).
Time frame: Baseline, Day 8 of each treatment period
Change From Baseline in the Mean Mismatch Negativity (MMN) at Day 8
MMN is an event related potential (ERP) evoked in response to unattended changes in background stimulation. MMN reflects an automatic process of detecting a mismatch between a deviant stimulus and a sensory-memory trace. Smaller amplitudes of MMN have been consistently identified in schizophrenia participants. MMN amplitude was measured at midline frontal electrode (Fz) of electroencephalogram (EEG). Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.
Time frame: Baseline, Day 8 of each treatment period
Change From Baseline in the Mean P300 Amplitude at Day 8
The P300 wave is an ERP component that is elicited by the presentation of a novel, behaviorally relevant target stimulus embedded among irrelevant stimuli in a manner similar to MMN but requiring active listening and responding from participants. Auditory stimuli are presented in an oddball paradigm consisting of 1 standard tone and 1 target tone. Participants are instructed to push a button as quickly as possible when they hear the target tone but not when they hear the standard tone. P300 reflects allocation of attention and activation of immediate memory. P300 amplitude was measured at midline parietal electrode (Pz) of EEG. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.
Time frame: Baseline, Day 8 of each treatment period
Change From Baseline in the Mean Auditory Steady State Response (ASSR) at Day 8
ASSRs are evoked oscillatory responses that are entrained to the frequency and phase of temporally modulated stimuli. Individuals with schizophrenia experience subjective sensory anomalies and objective deficits on assessment of sensory function. These deficits can be produced by abnormal signaling in the sensory pathways and sensory cortex or by later-stage disturbances in the cognitive processing of such inputs. ASSR can be used to assess the integrity of sensory pathways including cortical processing. The ASSR applied a frequency stimulus of 40 hertz (Hz) and was measured at midline central electrode (Cz) of EEG. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.
Time frame: Baseline, Day 8 of each treatment period
Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Day 7
BACS is a cognition assessment battery and includes brief assessments of reasoning and problem solving, verbal fluency, attention, verbal memory, working memory and motor speed. The primary measure from each test is standardized by creating z-scores whereby the mean of the test session of a healthy person is set to 0 and the standard deviation set to 1. A Z-score of 0 represents the population mean. A composite score was calculated by averaging the 4 measures from the BACS used in the study and then calculating a z-score of the composite. The composite z-score indicates how much higher or lower the participants cognition is compared to a healthy person. Lower z-scores are indicative of lower cognitive performance. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 7, determined using an ANOVA.
Time frame: Baseline, Day 7 of each treatment period
Change From Baseline in the Mean Plasma Concentrations of D-serine and L-serine at Day 8
Blood samples were collected at pre-specified timepoints and plasma concentrations of D-serine and L-serine were measured. Results are reported as LS mean change from baseline at Day 8, determined using a mixed model for repeated measures (MMRM).
Time frame: Day 1 and at multiple time points (up to 6 hours) to Day 8 pre-dose
Change From Baseline in the Mean Plasma D-serine to Total Serine Ratio at Day 8
Blood samples were collected at pre-specified timepoints and plasma concentrations of D-serine and total serine were measured. Plasma D-serine to total serine ratios were then calculated. Results are reported as LS mean change from baseline at Day 8, determined using a MMRM.
Time frame: Baseline and Day 8 of each treatment period
Mean Plasma Concentration of Luvadaxistat
Blood samples were collected at pre-specified timepoints and plasma concentrations of luvadaxistat were measured.
Time frame: Day 1 0.25 to 2 hours and 3 to 6 hours post-dose, Day 7 pre-dose, 0.25 to 2 hours and 3 to 6 hours post-dose, and Day 8 pre-dose
Participants took part in the study at 1 investigative site in the United States from 10 January 2018 to 21 December 2020.
| Milestone | Luvadaxistat 500 mg, Then Placebo | Placebo, Then Luvadaxistat 500 mg | Luvadaxistat 50 mg, Then Placebo | Placebo, Then Luvadaxistat 50 mg |
|---|---|---|---|---|
| Started | 8 | 9 | 7 | 7 |
| Completed | 6 | 6 | 5 | 7 |
| Not completed | 2 | 3 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Early study termination due to study pause | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 | 0 |
EBC is a method used to investigate cerebellar-dependent learning. In EBC, a conditioned stimulus, a tone precedes but co-terminates with an unconditioned stimulus, an airpuff to the eyelid. Learning is demonstrated when an eyeblink (the conditioned response) occurs prior to the onset of the unconditioned stimulus. The percentage can range from 0% (no conditioned learning has occurred) to 100% (all responses are conditioned). Results are reported as least squares (LS) means at Day 8, determined using an analysis of variance (ANOVA).
| Percent of Conditioned Responses | Luvadaxistat 50 mg | Placebo (Reference for Luvadaxistat 50 mg) | Luvadaxistat 500 mg | Placebo (Reference for Luvadaxistat 500 mg) |
|---|---|---|---|---|
| Change From Baseline in Average Percent of Conditioned Responses During the Eye Blink Conditioning (EBC) Test at Day 8 | 0.597 ± 0.459 | 0.319 ± 0.432 | 0.578 ± 0.444 | 1.344 ± 0.428 |
MMN is an event related potential (ERP) evoked in response to unattended changes in background stimulation. MMN reflects an automatic process of detecting a mismatch between a deviant stimulus and a sensory-memory trace. Smaller amplitudes of MMN have been consistently identified in schizophrenia participants. MMN amplitude was measured at midline frontal electrode (Fz) of electroencephalogram (EEG). Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.
| microvolts | Luvadaxistat 50 mg | Placebo (Reference for Luvadaxistat 50 mg) | Luvadaxistat 500 mg | Placebo (Reference for Luvadaxistat 500 mg) |
|---|---|---|---|---|
| Change From Baseline in the Mean Mismatch Negativity (MMN) at Day 8 | -0.239 ± 0.363 | 0.669 ± 0.382 | 0.594 ± 0.492 | -0.154 ± 0.501 |
The P300 wave is an ERP component that is elicited by the presentation of a novel, behaviorally relevant target stimulus embedded among irrelevant stimuli in a manner similar to MMN but requiring active listening and responding from participants. Auditory stimuli are presented in an oddball paradigm consisting of 1 standard tone and 1 target tone. Participants are instructed to push a button as quickly as possible when they hear the target tone but not when they hear the standard tone. P300 reflects allocation of attention and activation of immediate memory. P300 amplitude was measured at midline parietal electrode (Pz) of EEG. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.
| microvolts | Luvadaxistat 50 mg | Placebo (Reference for Luvadaxistat 50 mg) | Luvadaxistat 500 mg | Placebo (Reference for Luvadaxistat 500 mg) |
|---|---|---|---|---|
| Change From Baseline in the Mean P300 Amplitude at Day 8 | -2.019 ± 1.68 | 0.608 ± 1.68 | 1.102 ± 1.77 | 2.595 ± 1.86 |
ASSRs are evoked oscillatory responses that are entrained to the frequency and phase of temporally modulated stimuli. Individuals with schizophrenia experience subjective sensory anomalies and objective deficits on assessment of sensory function. These deficits can be produced by abnormal signaling in the sensory pathways and sensory cortex or by later-stage disturbances in the cognitive processing of such inputs. ASSR can be used to assess the integrity of sensory pathways including cortical processing. The ASSR applied a frequency stimulus of 40 hertz (Hz) and was measured at midline central electrode (Cz) of EEG. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.
| microvolts-squared | Luvadaxistat 50 mg | Placebo (Reference for Luvadaxistat 50 mg) | Luvadaxistat 500 mg | Placebo (Reference for Luvadaxistat 500 mg) |
|---|---|---|---|---|
| Change From Baseline in the Mean Auditory Steady State Response (ASSR) at Day 8 | 2.135 ± 8.83 | -16.282 ± 9.31 | 9.411 ± 20.4 | 9.203 ± 20.9 |
BACS is a cognition assessment battery and includes brief assessments of reasoning and problem solving, verbal fluency, attention, verbal memory, working memory and motor speed. The primary measure from each test is standardized by creating z-scores whereby the mean of the test session of a healthy person is set to 0 and the standard deviation set to 1. A Z-score of 0 represents the population mean. A composite score was calculated by averaging the 4 measures from the BACS used in the study and then calculating a z-score of the composite. The composite z-score indicates how much higher or lower the participants cognition is compared to a healthy person. Lower z-scores are indicative of lower cognitive performance. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 7, determined using an ANOVA.
| z-score | Luvadaxistat 50 mg | Placebo (Reference for Luvadaxistat 50 mg) | Luvadaxistat 500 mg | Placebo (Reference for Luvadaxistat 500 mg) |
|---|---|---|---|---|
| Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Day 7 | 2.574 ± 2.51 | 5.070 ± 2.55 | 5.696 ± 1.41 | -0.075 ± 1.43 |
Blood samples were collected at pre-specified timepoints and plasma concentrations of D-serine and L-serine were measured. Results are reported as LS mean change from baseline at Day 8, determined using a mixed model for repeated measures (MMRM).
| mg / liter | Luvadaxistat 50 mg | Placebo (Reference for Luvadaxistat 50 mg) | Luvadaxistat 500 mg | Placebo (Reference for Luvadaxistat 500 mg) |
|---|---|---|---|---|
| D-serine | 0.0402 ± 0.00632 | -0.000892 ± 0.00637 | 0.0398 ± 0.00710 | 0.00212 ± 0.00712 |
| L-serine | 0.669 ± 0.479 | -0.543 ± 0.483 | -1.09 ± 0.514 | -0.304 ± 0.516 |
Blood samples were collected at pre-specified timepoints and plasma concentrations of D-serine and total serine were measured. Plasma D-serine to total serine ratios were then calculated. Results are reported as LS mean change from baseline at Day 8, determined using a MMRM.
| ratio | Luvadaxistat 50 mg | Placebo (Reference for Luvadaxistat 50 mg) | Luvadaxistat 500 mg | Placebo (Reference for Luvadaxistat 500 mg) |
|---|---|---|---|---|
| Change From Baseline in the Mean Plasma D-serine to Total Serine Ratio at Day 8 | 0.00293 ± 0.000855 | 0.000590 ± 0.000863 | 0.00561 ± 0.000994 | 0.000620 ± 0.000997 |
Blood samples were collected at pre-specified timepoints and plasma concentrations of luvadaxistat were measured.
| nanograms / milliliter | Luvadaxistat 50 mg | Luvadaxistat 500 mg |
|---|---|---|
| Day 1 - Post-dose (0.25 to 2 hours) | 253.4 ± 199.3 | 700.4 ± 783.0 |
| Day 1 - Post-dose (3 to 6 hours) | 47.66 ± 35.64 | 671.1 ± 473.1 |
| Day 7 - Pre-dose | 8.749 ± 19.212 | 78.92 ± 229.90 |
| Day 7 - Post-dose (0.25 to 2 hours) | 203.5 ± 199.6 | 1184 ± 482 |
| Day 7 - Post-dose (3 to 6 hours) | 38.94 ± 26.23 | 301.5 ± 177.2 |
| Day 8 - Pre-dose | 3.366 ± 2.726 | 21.61 ± 14.65 |
Collected over 8-day treatment period for each of treatment periods 1 and 2 (separated by washout of up to 21 days) and up to 30 days follow-up after last dose of study treatment. Up to a maximum of 67 days for overall timeframe.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) |
| Luvadaxistat 500 mg | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Luvadaxistat 50 mg | 0/14 (0%) | 0/14 (0%) | 1/14 (7.1%) |
| Event | Placebo | Luvadaxistat 500 mg | Luvadaxistat 50 mg |
|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 0/29 | 0/15 | 1/14 |
The safety analysis set included all participants who were randomized and received at least 1 dose of double-blind study drug.
| Age, Categorical(Participants) | Luvadaxistat 500 mg, Then Placebo | Placebo, Then Luvadaxistat 500 mg | Luvadaxistat 50 mg, Then Placebo | Placebo, Then Luvadaxistat 50 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 9 | 7 | 7 | 31 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Luvadaxistat 500 mg, Then Placebo | Placebo, Then Luvadaxistat 500 mg | Luvadaxistat 50 mg, Then Placebo | Placebo, Then Luvadaxistat 50 mg | Total |
|---|---|---|---|---|---|
| Female | 0 | 2 | 1 | 2 | 5 |
| Male | 8 | 7 | 6 | 5 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Luvadaxistat 500 mg, Then Placebo | Placebo, Then Luvadaxistat 500 mg | Luvadaxistat 50 mg, Then Placebo | Placebo, Then Luvadaxistat 50 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 8 | 9 | 6 | 7 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Luvadaxistat 500 mg, Then Placebo | Placebo, Then Luvadaxistat 500 mg | Luvadaxistat 50 mg, Then Placebo | Placebo, Then Luvadaxistat 50 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 8 | 6 | 4 | 26 |
| White | 0 | 1 | 0 | 2 | 3 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Dec 2020, 35 months.
Results were first posted in Feb 2024, 3 years 2 months after primary completion. A results delay was requested in Dec 2021.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 35 months is above that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Luvadaxistat